Bronchial Biopsy Devices Market Increasing Demand, Growth Analysis and Future Outlook by 2031

The global bronchial biopsy devices market is anticipated to grow at a CAGR of 7.4% during the forecast period (2024-2031). Consistent FDA approval and continuous financial support are key drivers fostering growth in the bronchial biopsy devices market. The constant FDA approval attributes adherence to rigorous regulatory standards, instilling confidence in the safety and efficacy of these devices. In January 2023, Micronoma, INC., obtained FDA breakthrough device designation for OncobiotaLUNG, a novel liquid biopsy assay for lung carcinoma detection. OncobiotaLUNG is a minimally-invasive liquid biopsy analyzing tumor DNA and proteins in 500? l of plasma, eliminating the need for tissue biopsy. It categorizes pulmonary nodules into high risk and low risk, guiding physicians in tailored management prompt follow-up for high-risk nodules and adherence to guidelines for low-risk nodules. In recent years, technical advancements in endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) bronchial biopsy have significantly improved diagnostic capabilities and procedural efficiency. In October 2023, Praxis Medical secured 510(k) clearance from the US Food and Drug Administration (FDA) for its EndoCore Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) fine needle biopsy device. The EndoCore EBUS-TBNA biopsy device is designed for the diagnosis and staging of lung cancer and involves the insertion of a long, flexible tiny needle through a bronchoscope to perform a biopsy and pathological analysis.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bronchial-biopsy-devices-market

Further, the growing emergence of more front-line devices such as liquid biopsy are also contributing to the market growth. Liquid biopsy is minimally invasive, typically requiring a blood sample, avoiding the need for traditional tissue biopsies. For instance, in August 2020, Guardant Health, Inc., received US Food and Drug Administration approval on the Guardant360 CDx, the first liquid biopsy companion diagnostic that also used next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies NGS and liquid biopsy in one diagnostic test in order to guide treatment decisions.

Global Bronchial Biopsy Devices Market Report Segment

By Product

• Biopsy Forceps
• Transbronchial Needle Aspiration (Tbna) Needles
• Cytology Brushes
• Liquid Biopsy Instruments

By End-Use

• Hospitals
• Diagnostic Imaging Centers
• Research and Academic Institutes
• Others

A full report of Bronchial Biopsy Devices Market available @ https://www.omrglobal.com/industry-reports/bronchial-biopsy-devices-market

Bronchial Biopsy Devices Market Report Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Argon Medical Devices Inc.
• B. Braun Medical Inc.
• Boston Scientific Corp.
• Cardinal Health, Inc.
• F. Hoffmann-La Roche AG
• Fujifilm Corp.
• Hobbs Medical Inc.
• Hologic, Inc.
• Horizons International Corp.
• INRAD Inc.
• NeoGenomics Laboratories, Inc

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.